Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
- improving the appropriate prescribing and use of medications
- increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data
- reducing drug system duplication and lack of coordination
CADTH adopted the new name Canada’s Drug Agency (CDA-AMC) as of May 1, 2024. An official launch will occur later this year.
Call for Operating Grant Proposals from LLSC
Canadian researchers are invited to submit proposals to The Leukemia & Lymphoma Society of Canada’s (LLSC) Operating Grant program for research aimed at preventing, detecting and treating all types of blood cancers. The application process consists of two phases. The first phase is submission and consid... Read More »
Canadian researchers are invited to submit proposals to The Leukemia & Lymphoma Society of Canada’s (LLSC) Operating Grant program for research aimed at preventing, detecting and treating all types of blood cancers. The application process consists of two phases. The first phase is submission and consid... Read More »
Refreshed CCRA Advisory Board
Effective January 1st, 2021, CCRA welcomes new Advisory Board chair, Dr. Paula Robson. Paula is the Scientific Director of the Cancer Strategic Clinical Network, and Scientific Director and co-lead of Cancer Research & Analytics for Cancer Care Alberta in Alberta Health Services.... Read More »
Effective January 1st, 2021, CCRA welcomes new Advisory Board chair, Dr. Paula Robson. Paula is the Scientific Director of the Cancer Strategic Clinical Network, and Scientific Director and co-lead of Cancer Research & Analytics for Cancer Care Alberta in Alberta Health Services.... Read More »